Retinal Pigment Epithelium Cell Derivation from Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for retinal degeneration and related visual disorders, such as age-related macular degeneration and retinitis pigmentosa, are inadequate due to the lack of effective means to reconstitute retinal pigment epithelium (RPE) cells, leading to functional disconnection between grafts and the host retina, and reliance on limited fetal tissue sources.
Innovation Solution
Development of methods to derive RPE and RPE-like cells from human embryonic stem cells, which can be differentiated and transplanted into the subretinal space using vitrectomy surgery, potentially overcoming graft rejection issues and expanding treatment availability beyond donor tissue limitations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RPE cells are derived from fetal tissue for transplantation, then the cells can be used to treat retinal degeneration, but the treatment is limited by donor tissue availability and may face graft rejection
Solution Approach 1:
The patent uses embryonic stem cells to generate RPE cells that replicate the function of donor fetal tissue without relying on limited donor supplies. The stem cell-derived cells are differentiated in vitro to produce functional RPE cells for transplantation, effectively copying the therapeutic effect while overcoming donor availability constraints
Solution Approach 2:
The patent changes the source parameter from fetal tissue to embryonic stem cells, fundamentally altering the cell derivation approach. This parameter change enables unlimited cell production through stem cell proliferation while maintaining the therapeutic functionality needed for retinal degeneration treatment
2Reliability
If current therapies are used for retinal degeneration, then treatment options exist, but they fail to effectively reconstitute RPE cells and restore vision function
Solution Approach 1:
The patent performs preliminary differentiation of embryonic stem cells into RPE cells in vitro before transplantation. This preliminary action ensures that the cells are properly prepared and matured to perform RPE functions, addressing the failure of current therapies to effectively reconstitute functional RPE cells
Solution Approach 2:
The patent replaces conventional transplantation approaches with a stem cell-based system that involves cell derivation, differentiation, and controlled transplantation. This substitution enables effective RPE cell reconstitution by using programmable stem cell differentiation rather than direct tissue transplantation
3Productivity
If RPE cells are transplanted into the subretinal space, then vision restoration can occur, but graft rejection and functional disconnection remain problems
Solution Approach 1:
The patent uses embryonic stem cells as an intermediary source that can be differentiated into RPE cells with improved compatibility. The stem cell-derived cells serve as a mediator between the graft and host, providing better integration and reducing rejection compared to direct fetal tissue transplantation
Solution Approach 2:
The patent employs controlled differentiation protocols that monitor and adjust cell development to ensure proper maturation and integration. This feedback mechanism ensures that the RPE cells are optimally prepared for transplantation and will integrate functionally with the host retina, addressing the disconnection problem
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method enables the production of functional RPE cells that can integrate with the host retina, offering improved vision restoration and addressing the limitations of existing therapies by providing a scalable and immunocompatible cell source.
Implementation Method 1
Development of methods to derive RPE and RPE-like cells from human embryonic stem cells, which can be differentiated and transplanted into the subretinal space
Data Source
AI summary
This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.